enGene Therapeutics Inc.
ENGN
$1.70
$0.010.59%
NASDAQ
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.44% | 15.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.51% | -21.01% | |||
| Operating Income | -2.51% | 21.01% | |||
| Income Before Tax | -1.60% | 22.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.60% | 21.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.60% | 21.46% | |||
| EBIT | -2.51% | 21.01% | |||
| EBITDA | -2.56% | 21.15% | |||
| EPS Basic | 1.99% | 40.00% | |||
| Normalized Basic EPS | 0.37% | 41.75% | |||
| EPS Diluted | 1.99% | 40.00% | |||
| Normalized Diluted EPS | 0.37% | 41.75% | |||
| Average Basic Shares Outstanding | 3.66% | 30.91% | |||
| Average Diluted Shares Outstanding | 3.66% | 30.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||